Category: Teva
-
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease
•
This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Breadcrumb Trail Links GlobeNewswire Author of the article: Published Feb 22, 2025 • 10 minute…
-
Teva CEO responds to 25% share price fall
•
Since the publication of its financial results for 2024 at the end of January, the share price Teva Pharmaceutical Industries Ltd. (NYSE: Tifa;; level: Tiva) He fought for recovery, as about $ 6 billion from the maximum market has been eliminated, to the maximum of the current market of $…
-
Teva files to raise first capital since 2016
•
Teva Pharmaceutical Industries Ltd. (NYSE: Tifa;; level: Tiva) The cliff bulletin with the US Securities and Stock Exchange Committee (SEC), which will allow it to issue a variety of securities, including the US Wadih shares (ADSS), debt papers, purchase contracts, and units. The release bulletin at this stage of the…
-
Analysts remain positive on Teva
•
The quarterly and annual financial statements to the Teva Pharmaceutical Industries (Tase: TEVA; NYSE: TEVA) last Wednesday sent the company’s share price of 13.9 % a day, and the segment continued in the following days as well. In the end in New York on Friday, Tiva, headed by Richard Francis,…
-
Teva falls sharply on disappointing 2025 guidance
•
Teva Pharmaceutical Industries Ltd. (NYSE: Tifa;; level: Tiva) The reports season of Israeli companies were opened by publishing the financial results in the fourth and full year 2024. In the fourth quarter, the company reported revenues of $ 4.2 billion and NON-GAAP per share of $ 0.71, higher than analysts’…
-
US analysts list Teva, Wix in 2025 top picks
•
Two Israeli stocks were included in the 2025 top picks list of US analysts. Choose Bank of America Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa as one of its top picks in its survey of biopharmaceuticals while Cantor Fitzgerald chose the website building platform company WEX.COM…
-
Teva share price at 6-year high after trial results
•
Market value for Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa Yesterday, it rose by $5 billion, after the stock price jumped 26%. The sharp rise has once again made Teva the most valuable Israeli company on Wall Street, with a market capitalization of $23.7 billion —…
-
Teva jumps sharply on bowel disease drug results
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa The stock price opened 20% higher on Wall Street after the Israeli company announced positive results from the phase 2 clinical trial of Docavitog, which it is developing with Sanofi, to treat ulcerative colitis (UC) and Crohn’s disease (CD).…
-
Teva divests from Japanese JV with Takeda
•
The Israeli pharmaceutical company is selling its 51% stake in the joint venture to private equity firm J-Will Partners. Over the years Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa The Israeli company has struggled to break into the Japanese market, and the Israeli company announced over…
-
Teva reports seventh straight quarter of growth
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa It ended the third quarter with revenue of $4.33 billion and non-GAAP earnings per share of $0.69, beating the consensus of analysts who expected revenue of $4.12 billion and $0.66 per share. The share price rose by 7% on…
-
Teva reports seventh straight quarter of growth
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa It ended the third quarter with revenue of $4.33 billion and non-GAAP earnings per share of $0.69, beating the consensus of analysts who expected revenue of $4.12 billion and $0.66 per share. The share price rose by 7% on…
-
Teva leapfrogs Check Point as Israel’s most valuable company
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa Once again the most valuable company in Israel. Tifa jumped Check Point Software Technologies Limited (Nasdaq: CHKP) on Wall Street after the cybersecurity company’s stock price fell due to missing third-quarter billing revenue and disappointing fourth-quarter guidance, which was…
-
Teva leapfrogs Check Point as Israel’s most valuable company
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa Once again the most valuable company in Israel. Tifa jumped Check Point Software Technologies Limited (Nasdaq: CHKP) on Wall Street after the cybersecurity company’s stock price fell due to missing third-quarter billing revenue and disappointing fourth-quarter guidance, which was…
-
Teva settles further price-fixing lawsuits in the US
•
Teva Pharmaceutical Industries (TSX: TEVA, NYSE: TEVA) has settled another lawsuit alleging price-fixing in the United States. Teva will pay $450 million in court-approved settlements in the United States, one for $425 million and the other for $25 million, without admitting any wrongdoing. The settlement amounts will be distributed over…
-
Teva shareholder sues after $450m US settlement
•
Last weekend, Teva Pharmaceuticals Industries (Teva: TEVA, NYSE: TEVA) announced that it had reached a settlement with the US Department of Justice and would pay fines totaling $450 million, to be paid over six years, without admitting any wrongdoing. , to the defendants. Ending the lawsuits filed against it by…
-
Teva shareholder sues after $450m US settlement
•
Last weekend, Teva Pharmaceuticals Industries (Teva: TEVA, NYSE: TEVA) announced that it had reached a settlement with the US Department of Justice and would pay fines totaling $450 million, to be paid over six years, without admitting any wrongdoing. , to the defendants. Ending the lawsuits filed against it by…
-
Teva settles opioid suits in Israel
•
The opioid case involving the Israeli drug maker Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) has been implicated and has now been settled in Israel. The Economic Court in Tel Aviv approved the claims against Teva Israel in this matter, and among other rulings decided that…
-
Teva reports strong Q2 results, raises 2024 forecast
•
Teva Pharmaceutical Industries Co., Ltd. (New York Stock Exchange: Tifa; level: Tifa) reported strong second-quarter 2024 results and revised its outlook upward again. The company reported second-quarter revenue of $4.2 billion, up 7% from the same quarter in 2023. GAAP net loss in the second quarter was $846 million ($0.75…
-
Teva schizophrenia drug Phase III results excite analysts
•
Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) saw its share price rise by 12.8% yesterday, amid high trading volume, to its highest level in five years. The stock price of $15.74 gave it a market value of $17.8 billion, after the company reported first-quarter results with…
-
Teva loss narrows as revenue grows
•
With the recovery of the generic drug market in the United States Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) It ended the first quarter of 2024 with revenues of $3.81 billion, an increase of 4.3% from the first quarter of 2023, and above analysts’ expectations of…